Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrinopathy affecting reproductive-age women. Visfatin, an adipocytokine, and insulin resistance (IR) marker in diabetes since PCOS and diabetes share insulin resistance as an etiological factor, this study aimed to investigate visfatin as a predictive marker for IR and hyperandrogenemia in non-obese PCOS women and test its correlation to other parameters. A cross-sectional study conducted at the University Hospital recruited 140 women, divided into two groups. Group I (70/140, study group) was PCOS patients’ diagnosis based on 2003 Rotterdam criteria and Group II (70/140, healthy controls). Both were aged, and body mass index (BMI) matched. After a detailed history and general examination, the clinical, demographic, biochemical, hormonal, and metabolic parameters were taken for comparison’s sake. PCOS patients were subdivided according to the clinical or hormonal evidence of hyperandrogenemia into two groups: those with hyperandrogenemia and those without. Higher serum visfatin was estimated in the PCOS group (4.4 ± 1.7) versus healthy controls (3.1 ± 0.7) ng/mL, P < 0.0001. Significantly higher visfatin was confirmed in hyperandrogenic PCOS versus non-hyperandrogenic PCOS women (5.69 ± 1.1 vs. 2.76 ± 0.51 ng/mL). A strong correlation was found between visfatin versus hemoglobin A1c and free androgen index (FAI); r = 0.784 and 0.624, respectively. BMI and free testosterone scored a modest correlation. BMI centiles’ correlation with serum visfatin revealed no significant effect on serum visfatin, P = 0.62. The ROC calculated visfatin cut-off value; 4.34 ng/mL with 51.4% sensitivity and 100% specificity, and a P-value < 0.001 in discriminating PCOS cases. In conclusion, a strong positive correlation of visfatin with insulin resistance, followed by FAI in PCOS cases irrespective of BMI, suggests the intimate relation of visfatin in PCOS pathophysiology among non-obese women. Further research is warranted to explore this association’s therapeutic and prognostic value.
Similar content being viewed by others
Data Availability
The data that supports the findings of this study is available from the University Hospital.
Code Availability
Not applicable.
Abbreviations
- BMI:
-
Body mass index
- SBP:
-
Systolic blood pressure
- DBP:
-
Diastolic blood pressure
- SHBG:
-
Sex hormone-binding globulin
- FAI:
-
Free androgen index
- LH:
-
Luteinizing hormone
- FSH:
-
Follicular stimulating hormone
- OGTT:
-
Oral glucose tolerance test
- HDL cholesterol:
-
High-density lipoprotein cholesterol
- LDL:
-
Low-density lipoprotein
- HA1c:
-
Glycosylated hemoglobin A1c
- PE:
-
Preeclampsia
References
Eiras MC, Pinheiro DP, Romcy K, Ferriani RA, Reis R, Furtado C. Polycystic ovary syndrome: the epigenetics behind the disease. Reprod Sci (Thousand Oaks Calif). 2022;29(3):680–94. https://doi.org/10.1007/s43032-021-00516-3.
Melo AS, Vieira CS, Romano LG, Ferriani RA, Navarro PA. The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Reprod Sci (Thousand Oaks Calif). 2011;18(12):1230–6. https://doi.org/10.1177/1933719111414205.
Al Ali, Nori W, Alrawi S. A copeptin as a predictor marker for insulin resistance among women with polycystic ovary syndrome. Curr Womens Health Rev. 2021;17:081221198670.
Chen F, Liao Y, Chen M, Yin H, Chen G, Huang Q, Chen L, Yang X, Zhang W, Wang P, Yin G. Evaluation of the efficacy of sex hormone-binding globulin in insulin resistance assessment based on HOMA-IR in patients with PCOS. Reprod Sci (Thousand Oaks, Calif). 2021;28(9):2504–13. https://doi.org/10.1007/s43032-021-00535-0.
Weickert MO, Hodges P, Tan BK, Randeva HS. Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. Minerva Endocrinol. 2012;37(1):25–40.
Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reprod (Oxford, England). 2013;28(3):777–84. https://doi.org/10.1093/humrep/des463.
Li L, Feng Q, Ye M, He Y, Yao A, Shi K. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol J Instit Obstet Gynaecol. 2017;37(8):1036–47. https://doi.org/10.1080/01443615.2017.1318840.
Plati E, Kouskouni E, Malamitsi-Puchner A, Boutsikou M, Kaparos G, Baka S. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril. 2010;94:1451–6. https://doi.org/10.1016/j.fertnstert.2009.04.055.
Yang X, Wang J. The role of metabolic syndrome in endometrial cancer: a review. Front Oncol. 2019;9:744. https://doi.org/10.3389/fonc.2019.00744.
Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril. 2010;93:880–4. https://doi.org/10.1016/j.fertnstert.2008.10.058.
Roomi AB, Nori W, Al-Badry SH. The value of serum adiponectin in osteoporotic women: does weight have an effect? J Obesity. 2021;2021:5325813. https://doi.org/10.1155/2021/5325813.
Dambala K, Paschou SA, Michopoulos A, Siasos G, Goulis DG, Vavilis D, Tarlatzis BC. Biomarkers of endothelial dysfunction in women with polycystic ovary syndrome. Angiology. 2019;70(9):797–801. https://doi.org/10.1177/0003319719840091.
Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med. 2005;11(8):344–7. https://doi.org/10.1016/j.molmed.2005.06.010.
Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem. 2008;15(18):1851–62. https://doi.org/10.2174/092986708785133004.
Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91(8):3165–70. https://doi.org/10.1210/jc.2006-0361.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. https://doi.org/10.1016/j.fertnstert.2003.10.004.
Wang Q, Jokelainen J, Auvinen J, Puukka K, Keinänen-Kiukaanniemi S, Järvelin MR, Kettunen J, Mäkinen VP, Ala-Korpela M. Insulin resistance and systemic metabolic changes in oral glucose tolerance test in 5340 individuals: an interventional study. BMC Med. 2019;17(1):217. https://doi.org/10.1186/s12916-019-1440-4.
Fox C, Bernardino L, Cochran J, Essig M, Bridges KG. Inappropriate use of homeostasis model assessment cutoff values for diagnosing insulin resistance in pediatric studies. J Am Osteo Assoc. 2017;117(11):689–96. https://doi.org/10.7556/jaoa.2017.135.
Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35:121. https://doi.org/10.4103/0253-7176.116232.
Kumari B, Yadav UCS. Adipokine visfatin’s role in pathogenesis of diabesity and related metabolic derangements. Curr Mol Med. 2018;18:116–25. https://doi.org/10.2174/1566524018666180705114131.
Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, Wolczynski S, Gorska M. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Human Reproduction. 2007;22:1824–9. https://doi.org/10.1093/humrep/dem118.
Kim JJ, Choi YM, Hong MA, Kim MJ, Chae SJ, Kim SM, Hwang KR, Yoon SH, Ku SY, Suh CS, Kim SH. Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls. Obstet Gynecol Sci. 2018;61:253–60. https://doi.org/10.5468/ogs.2018.61.2.253.
Rashad NM, Abd-Elrahman MA, Amal S, Amin AI. Association of miRNA−320 expression level and its target gene endothelin-1 with the susceptibility and clinical features of polycystic ovary syndrome. J Ovarian Res. 2019;12:1–10. https://doi.org/10.1186/s13048-019-0513-5.
Nourbakhsh M, Nourbakhsh M, Gholinejad Z, Razzaghy-Azar M. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Scand J Clin Lab Invest. 2015;75:183–8. https://doi.org/10.3109/00365513.2014.1003594.
Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril. 2010;93:880–4. https://doi.org/10.1016/j.fertnstert.2008.10.058.
Nori W, Hamed RM, Roomi AB, Akram W Alpha-1 antitrypsin in pre-eclampsia; from a clinical perspective. J Pak Med Assoc 2021 71: S53–56. (Suppl. 8). https://jpma.org.pk/supplement-article-details/670.
Shaheen A, Nazli R, Fatima S, Ali R, Khan I, Khattak S Adipokine serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy. Pakistan J Med Sci 2016 32: 1419. https://doi.org/10.12669/pjms.326.1091.
Güdücü N, İşçi H, Görmüş U, Yiğiter AB, Dünder I. Serum visfatin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28(8):619–23. https://doi.org/10.3109/09513590.2011.650749.
Dıkmen E, Tarkun I, Cantürk Z, Cetınarslan B. Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol. 2011;27(7):475–9. https://doi.org/10.3109/09513590.2010.495796.
Pantoja-Torres B, Toro-Huamanchumo CJ, Urrunaga-Pastor D, Guarnizo-Poma M, Lazaro-Alcantara H, Paico-Palacios S, Del Carmen Ranilla-Seguin V, Benites-Zapata VA, Insulin Resistance and Metabolic Syndrome Research Group. High triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight healthy adults. Diabetes Metab Syndr. 2019;13(1):382–8. https://doi.org/10.1016/j.dsx.2018.10.006.
Krentowska A, Kowalska I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes Metab Res Rev. 2022;38(1):e3464. https://doi.org/10.1002/dmrr.3464.
Solem RC. Limitation of a cross-sectional study. Am J Orthod Dentofac Orthop. 2015;148(2):205. https://doi.org/10.1016/j.ajodo.2015.05.006.
Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, Granese R, Triolo O. Metabolism and ovarian function in PCOS women: a therapeutic approach with inositols. Int J Endocrinol. 2016;2016:6306410. https://doi.org/10.1155/2016/6306410.
Paul C, Laganà AS, Maniglio P, Triolo O, Brady DM. Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. Gynecol Endocrinol. 2016;32(6):431–8. https://doi.org/10.3109/09513590.2016.1144741.
Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Noroozzadeh M, Farahmand M, Rostami Dovom M, Ramezani Tehrani F. The risk of metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Clin Endocrinol. 2018;88(2):169–84. https://doi.org/10.1111/cen.13477.
Acknowledgements
We acknowledge Al-Mustansiriyah University, Baghdad, Iraq.
Author information
Authors and Affiliations
Contributions
Al: research idea, study design, data collection, data analysis, manuscript writing. WN: manuscript writing, data analysis, scientific editing, and literature review. Manuscript writing was equally shared by both authors. The authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics Approval
Ethical approval had been taken from the Ethical Committee of Mustansiriyah Medical College.
Consent to Participate
Informed written and verbal consent was taken from all participants.
Consent for Publication
Not applicable.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ali, A.I., Nori, W. Correlation of Serum Visfatin Level in Non-obese Women with Polycystic Ovary Syndrome and Matched Control. Reprod. Sci. 29, 3285–3293 (2022). https://doi.org/10.1007/s43032-022-00986-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43032-022-00986-z